Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castration-resistant Prostate Cancer (CRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03737370
What this trial is testing

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer
Tufts Medical Center 43
Testing effectiveness (Phase 2)Study completedNCT02012920
What this trial is testing

Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate CancerCRPC
Innocrin Pharmaceutical 200
Early research (Phase 1)Study completedNCT01634061
What this trial is testing

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Who this might be right for
Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 43
Testing effectiveness (Phase 2)Study completedNCT01051570
What this trial is testing

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Who this might be right for
Prostate Cancer
Barbara Ann Karmanos Cancer Institute 26
Not applicableUnknownNCT01590498
What this trial is testing

Radiotherapy vs Observation for CRPC

Who this might be right for
Hormone Refractory Prostate Cancer
Zhengzhou University 2,000
Testing effectiveness (Phase 2)Study completedNCT01171898
What this trial is testing

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 127
Testing effectiveness (Phase 2)Ended earlyNCT05553639
What this trial is testing

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Hookipa Biotech GmbH 12
Early research (Phase 1)Temporarily pausedNCT04053062
What this trial is testing

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Who this might be right for
Castrate-Resistant Prostate Cancer
Bioray Laboratories 12
Early research (Phase 1)UnknownNCT05836623
What this trial is testing

A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions

Who this might be right for
Advanced and/or Metastatic Solid Tumours
Crescendo Biologics Ltd. 5
Very early researchWithdrawnNCT07052760
What this trial is testing

Imaging of Solid Tumors Using DLL3 SPECT

Who this might be right for
Solid Tumor CancerCastration Resistant Prostate CancerCastration Resistant Prostate Cancer (CRPC)+1 more
Thomas Hope
Testing effectiveness (Phase 2)UnknownNCT01630967
What this trial is testing

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Neoplasm
British Columbia Cancer Agency 40
Large-scale testing (Phase 3)Ended earlyNCT02438007
What this trial is testing

Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

Who this might be right for
Prostate Cancer
LTN PHARMACEUTICALS, INC. 953
Testing effectiveness (Phase 2)Study completedNCT01424930
What this trial is testing

Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate NeoplasmsProstate Cancer
Janssen-Ortho Inc., Canada 25
Early research (Phase 1)Study completedNCT01884285
What this trial is testing

AZD8186 First Time In Patient Ascending Dose Study

Who this might be right for
Advanced Castrate-resistant Prostate Cancer CRPCSquamous Non-Small Cell Lung Cancer sqNSCLCTriple Negative Breast Cancer TNBC
AstraZeneca 147
Testing effectiveness (Phase 2)Study completedNCT01270880
What this trial is testing

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Barbara Ann Karmanos Cancer Institute 18
Early research (Phase 1)Ended earlyNCT00933426
What this trial is testing

Lenalidomide and Paclitaxel in Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT01688492
What this trial is testing

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 54
Testing effectiveness (Phase 2)Ended earlyNCT01469338
What this trial is testing

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Who this might be right for
DiarrheaHormone-resistant Prostate CancerRecurrent Prostate Cancer+5 more
University of Southern California 9
Not applicableStudy completedNCT02141438
What this trial is testing

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Bayer 1,472
Not applicableUnknownNCT04188275
What this trial is testing

CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION

Who this might be right for
D011471D064129D035683+2 more
Azienda Ospedaliero-Universitaria Careggi 46
Next Page